These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7758054)

  • 61. Safety of the Up-titration of Nifedipine GITS and Valsartan or Low-dose Combination in Uncontrolled Hypertension: the FOCUS Study.
    Park JB; Shin JH; Kim DS; Youn HJ; Park SW; Shim WJ; Park CG; Kim DW; Lee HY; Choi DJ; Rim SJ; Lee SY; Kim JH;
    Clin Ther; 2016 Apr; 38(4):832-42. PubMed ID: 26996246
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group.
    Hedner T; Himmelmann A
    J Hypertens; 1999 Jan; 17(1):129-36. PubMed ID: 10100104
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension.
    Os I; Stokke HP
    Blood Press; 1999; 8(3):184-91. PubMed ID: 10595697
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris.
    Wallace WA; Wellington KL; Chess MA; Liang CS
    Am J Cardiol; 1994 Jan; 73(1):23-8. PubMed ID: 8279372
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses.
    Kjeldsen SE; Cha G; Villa G; Mancia G;
    J Clin Pharmacol; 2016 Sep; 56(9):1120-9. PubMed ID: 26829251
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antihypertensive efficacy of a slow release nifedipine tablet formulation given once daily in patients with mild to moderate hypertension. A placebo-controlled, double-blind parallel-group trial.
    Harder S; Rietbrock S; Thürmann P
    Arzneimittelforschung; 1994 Feb; 44(2):133-6. PubMed ID: 8147945
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparative efficacy of two long-acting formulations of nifedipine in the treatment of hypertension. The Switch Study Investigators.
    Myers MG; Toal CB
    Can J Cardiol; 1995 Nov; 11(10):913-7. PubMed ID: 7489530
    [TBL] [Abstract][Full Text] [Related]  

  • 69. 24 hour blood pressure control with once-daily versus twice-daily formulations of diltiazem.
    Ruddy TD; Wright JM; Savard D; Handa SP; Chockalingam A; Fischer L; Boulet AP
    Cardiovasc Drugs Ther; 1995 Dec; 9(6):799-807. PubMed ID: 8850385
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
    Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
    Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.
    Murdoch D; Brogden RN
    Drugs; 1991 May; 41(5):737-79. PubMed ID: 1712708
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study.
    Shimamoto K; Hasebe N; Ito S; Kario K; Kimura K; Dohi Y; Kawano Y; Rakugi H; Horiuchi M; Imaizumi T; Ohya Y
    Hypertens Res; 2014 Jan; 37(1):69-75. PubMed ID: 23945965
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension.
    Houston MC; Olafsson L; Burger MC
    Angiology; 1991 Sep; 42(9):681-90. PubMed ID: 1928808
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antihypertensive effects of a new sustained-release formulation of nifedipine.
    Zachariah PK; Schwartz GL; Sheps SG; Schirger A; Carlson CA; Moore AG
    J Clin Pharmacol; 1990 Nov; 30(11):1012-9. PubMed ID: 2243148
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Equivalent reduction of proteinuria in hypertensives by either nifedipine GITS or enalapril: disparate effects on neurohormones and ambulatory blood pressure and the influence of salt.
    DeQuattro V; Lee DP
    Cardiology; 1997; 88 Suppl 3():38-42. PubMed ID: 9397292
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
    Brown MJ; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
    J Hypertens; 1998 Dec; 16(12 Pt 2):2113-6. PubMed ID: 9886905
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of mild hypertension with low once-daily doses of a sustained-release capsule formulation of verapamil.
    Davis PJ; Fagan TC; Topmiller MJ; Levine JH; Ferdinand KC
    J Clin Pharmacol; 1995 Jan; 35(1):52-8. PubMed ID: 7751413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.